EANS-News: Intercell completed the acquisition of Cytos' antibody technology platform
Vienna (Austria), June 8, 2010 (euro adhoc) -
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement.
Strategic management decisions
Intercell AG (VSE: ICLL) today announced the closing of the acquisition of Cytos' platform technology for monoclonal antibody discovery. On May 6, 2010 Intercell had announced the intent to acquire that technology, which is based on expression cloning of monoclonal antibodies from human B-cells, for EUR 15m.
The antibody technology complements Intercell's technology platforms and opens novel medically and commercially relevant applications for Intercell's Antigen Identification Program (AIP®).
end of announcement euro adhoc
Further inquiry note:
Intercell AG
Lucia Malfent
Vice President, Global Head Corporate Communications
Tel. +43 1 20620-1303
lmalfent@intercell.com
Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wien / official market